SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Library > Case Study

Advancing therapeutics for myeloma

Format: PDF file | Document type: Case Study
Ocopeptides

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement for more efficient and tolerable therapies.

Oncopeptides, a clinical stage company, has partnered with Recipharm's analytical chemistry team to help take a promising molecule from the discovery phase to clinical trials, with the end goal of commercial production. Download the full case study to read more about the project and Recipharm's development services.

LATEST CONTENT FROM Recipharm AB

Take steps to stay in the serialization race

As the deadline for drug serialization in the EU looms closer, it’s time to put the topic firmly on your agenda. Learn how to overcome the serialization challenge and simplify compliance.

Developing a new high throughput screen method to improve excipient selection for solubilisation

A new high throughput screen method designed to improve the efficiency of testing excipients to solubilise compounds could save companies time, money and resource.

Supplier's Info Centre

Recipharm AB